Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client‐owned dogs: A multicentre, double‐masked, randomised, placebo‐controlled clinical trial
Once daily ilunocitinib was well-tolerated and effective at rapidly reducing pruritus and resolving cAD-associated skin lesions. Clinical remission was achieved by two-thirds of dogs after 4 months of treatment. Ilunocitinib is safe and effective for managing clinical signs associated with cAD.
Authors
- Darren J. Berger (ORCID: https://orcid.org/0000-0002-7532-9797)
- Sophie Forster (ORCID: https://orcid.org/0000-0001-9991-5531)
- Candace M. Trout
- Stephen King (ORCID: https://orcid.org/0000-0002-5925-5038)
- Annette Boegel
- Simona Despa
Institutions
- Elanco (United States) (US)
Publication Details
- Journal
- Veterinary Dermatology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1111/vde.13344
- Citations
- 4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.02
Funders
- Elanco Animal Health